Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.43 |
| ▸ | HMGCR | P04035 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43254 | 0.87 | TAAR1 (0.59) | CYP3A4TAAR1GLALMNAALDH1A1 | |
| SCHEMBL30871956 | 0.85 | CYP3A4 (0.56) | CYP3A4TAAR1GLACYP19A1LMNA | |
| SCHEMBL490437 | 0.85 | CYP3A4 (0.56) | CYP3A4TAAR1GLACYP19A1LMNA | |
| SCHEMBL17718565 | 0.83 | CYP4F2 (0.49) | CYP3A4TAAR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL7193965 | 0.80 | CYP3A4 (0.51) | CYP3A4TAAR1GLACYP19A1ALDH1A1 | |
| SCHEMBL7827237 | 0.80 | NPSR1 (0.55) | CYP3A4TAAR1LMNAHTR2AHMGCR | |
| SCHEMBL6554363 | 0.80 | CYP3A4 (1.00) | CYP3A4TAAR1HTR2ATNFSF11MEN1 | |
| SCHEMBL2090274 | 0.79 | NPC1 (0.58) | CYP3A4CYP19A1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL266527 | 0.79 | NPC1 (0.58) | CYP3A4LMNAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL11077966 | 0.79 | MTNR1A (0.62) | CYP3A4TAAR1LMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995067-B2 | Treatment of Fabry disease | ACADEMIA SINICA (TW) | 2021-05-04 | — | — | US | disclosed |
| US-20190225579-A1 | TREATMENT OF FABRY DISEASE | ACADEMIA SINICA (TW) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225579-A1 | TREATMENT OF FABRY DISEASE | GBA2, GBA1, GAA | CYP3A4 4587/4885TAAR1 2941/4885GLA 6/4885 |
| US-10995067-B2 | Treatment of Fabry disease | GBA2, GBA1, GAA | CYP3A4 4587/4885TAAR1 2941/4885GLA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.